-
Mashup Score: 26Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis - 6 month(s) ago
This cohort study examines graded kidney response criteria and their association with kidney and overall survival for patients with kidney light chain amyloidosis.
Source: jamanetwork.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 60Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy - 7 month(s) ago
Daratumumab’s incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have su…
Source: www.tandfonline.comCategories: General Medicine News, Partners & KOLsTweet-
Our multicenter study led by @DimaDanai @MSHughes_MD on Venetoclax outcomes after Dara-failure in AL #Amyloidosis: VGPR rate ~90% Cardiac Organ RR~70% ~1 in 4 required another LoT at a median f/u of 22 mo. No treatment-related deaths! https://t.co/AiJHzttn4x
-
-
Mashup Score: 24TIMING AND OUTCOMES OF SECOND LINE THERAPY IN THE ERA OF... by Abdul-Hamid Bazarbachi - 8 month(s) ago
EHA Library; Bazarbachi A. Jun 13 2024; 421013;
Source: library.ehaweb.orgCategories: General Medicine News, Partners & KOLsTweet-
Timing and Outcomes of 2nd line therapy in the era of frontline Dara-VCd in AL #Amyloidosis-Our experience @CAMPamyloidosis to be presented at #EHA24 by @abazarbachi! @SLentzsch https://t.co/6o7lBqkzR8
-
-
Mashup Score: 3Distant Thunder (1973) ⭐ 7.9 | Drama - 9 month(s) ago
1h 41m | Not Rated
Source: m.imdb.comCategories: General Medicine News, Hem/OncsTweet-
@nihardesai7 @ParijatSen11 Reminds me of the iconic Satyajit Ray movie “Ashani Sanket”, a poignant portrayal of the tragedies during Bengal famine. https://t.co/9w1DDYz8jV
-
-
Mashup Score: 38AL amyloidosis response: a move in the “light” direction - 9 month(s) ago
As redemonstrated by Bomsztyk et al1 in this issue of Blood, top-down mass spectrometry (MS) of blood has been transformative for diagnosing and monitoring
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
👍🏽editorial by @ADispenzieri on FLC-Mass Spect in AL amyloidosis by @awechalekar's group. I love the way Dr. Dispenzieri masterfully distills the key findings in one figure! A must-read and should be a benchmark for how to write an excellent commentary. https://t.co/oEWRnHlnOq https://t.co/Ai6Jr0BNTC https://t.co/iXGuMV4DbP
-
-
Mashup Score: 35AL amyloidosis response: a move in the “light” direction - 9 month(s) ago
As redemonstrated by Bomsztyk et al1 in this issue of Blood, top-down mass spectrometry (MS) of blood has been transformative for diagnosing and monitoring
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
👍🏽editorial by @ADispenzieri on FLC-Mass Spect in AL amyloidosis by @awechalekar's group. I love the way Dr. Dispenzieri masterfully distills the key findings in one figure! A must-read and should be a benchmark for how to write an excellent commentary. https://t.co/oEWRnHlnOq https://t.co/Ai6Jr0BNTC https://t.co/iXGuMV4DbP
-
-
Mashup Score: 2First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy - PubMed - 9 month(s) ago
Although Dara-VCD (daratumumab-bortezomib-cyclophosphamide-dexamethasone) has revolutionized the treatment of newly diagnosed Amyloid Light chain (AL) amyloidosis, patients with stage IIIb disease were excluded in the pivotal trial. We performed a multicentre retrospective cohort study to investigat …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet-
Very similar to our multicenter retrospective study that showed encouraging efficacy with Dara-VCd in stage IIIb AL, with deep cardiac responses in many patients! https://t.co/TLypajQSOC https://t.co/qOtkXS3jRo
-
-
Mashup Score: 38
Not available.
Source: haematologica.orgCategories: General Medicine News, Partners & KOLsTweet-
Great to see prospective data on Dara-Vd in Stage IIIb AL #Amyloidosis! Hematologic and organ response comparable to ANDROMEDA and 2-year OS~65% (historically ~20%)! Proves that we can now successfully treat even stage IIIb! https://t.co/vvY0zqh4iR https://t.co/BR45DlmV9o https://t.co/GriqMN91Gh
-
-
Mashup Score: 4Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study - PubMed - 10 month(s) ago
Johnson & Johnson Pharmaceutical Research and Development, and Millennium Pharmaceuticals.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet-
@RahulBanerjeeMD @JanakiramMurali @HiraSMian @GKaurMD @JanssenUS @VincentRK Agree that RCT or once vs twice weekly V will never happen at this point (and I wouldn’t enroll my patient into it even if it did). However, we do have an RCT of IV vs sq Velcade, which likely led to widespread adoption of sq early on. (https://t.co/iVUzQ2ZlHW)
-
-
Mashup Score: 101Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma - 10 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Partners & KOLsTweet-
Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 @columbiacancer (led by @Slade_Mellgard)- Now out in @Hemasphere_EHA! #mmsm 🧵 https://t.co/nz5RrtjWS6 https://t.co/VvHYMgFxRI
-
Graded Kidney Response Criteria in AL #Amyloidosis! With improving therapies, a 30% or 50% reduction in proteinuria is no longer good enough. Impressive collaborative study by Dr. Muchtar and @MorieGertz! https://t.co/DqGkx2MrOo